European Pharma Oligonucleotide Consortium: A Move to Consolidate Oligonucleotide Knowledge and Share Experience Within the Community
Overview
Pharmacology
Authors
Affiliations
A consortium of seven pharma companies has been formed with the aim of sharing knowledge on and harmonizing approaches to oligonucleotide development. This letter aims to raise awareness of this new group and to set expectations for future publications.
Considerations for the Terminal Sterilization of Oligonucleotide Drug Products.
DeCollibus D, Searcy J, Tivesten A, Akhtar N, Lindenberg C, Abarrou N Nucleic Acid Ther. 2023; 33(3):159-177.
PMID: 36787481 PMC: 10277985. DOI: 10.1089/nat.2022.0073.
Solution Oligonucleotide APIs: Regulatory Considerations.
Wetter C, Chorley C, Curtis C, Del Canto N, Ford J, Franklin J Ther Innov Regul Sci. 2022; 56(3):386-393.
PMID: 35133632 PMC: 8964572. DOI: 10.1007/s43441-022-00384-2.
Technical Considerations for Use of Oligonucleotide Solution API.
Muslehiddinoglu J, Simler R, Hill M, Mueller C, Amery J, Dixon L Nucleic Acid Ther. 2020; 30(4):189-197.
PMID: 32379529 PMC: 7415879. DOI: 10.1089/nat.2020.0846.